U.K. stocks higher at close of trade; Investing.com United Kingdom 100 up 0.25%

U.K. stocks rose as Mining, Aerospace & Defense led gains; Pearson reached 5-year highs while Segro hit 52-week lows. Commodities and currency rates remained stable.

Vaccine stocks drop as Trump picks RFK Jr for US health job

Vaccine stocks fell sharply after Donald Trump nominated Robert F. Kennedy Jr., a vaccine skeptic, as Secretary of HHS, raising concerns over future public health policies.

FTSE 100 subdued as pharma stocks weigh

UK stock indexes struggled as AstraZeneca and GSK fell amidst an unexpected economic contraction, causing setbacks for growth plans despite some gains in mining and property sectors.

Earnings call: GSK reports strong Q3 growth, optimistic for 2024

Shares of GSK down as weak vaccine sales cast shadow on earnings beat

GSK shares dropped over 3% after disappointing Q3 2024 earnings, driven by lackluster vaccine sales and uncertain future growth despite maintaining EPS guidance.

GSK warns of lower 2024 vaccine sales after weaker RSV, shingles demand

GSK reports declining vaccine sales due to weak RSV and shingles performance, revises forecasts downward, while maintaining optimism for medium- and long-term growth.

GSK shares jump after $2.2 bln settlement for 80,000 Zantac lawsuits

GSK settles approximately 80,000 lawsuits related to Zantac for up to $2.2 billion, boosting shares, while denying any liability amidst ongoing litigation.

European stocks edge up ahead of US inflation data, GSK jumps

European stocks rose as markets await U.S. inflation data; GSK shares jumped after a settlement, while BMW sales declined and Givaudan shares increased.

GSK shares jump after settlement of 80,000 Zantac lawsuits in U.S

GSK's shares jumped 6% as the drugmaker settled Zantac lawsuits for up to $2.2 billion, resolving most pending cases while admitting no wrongdoing.

GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion

GSK will pay $2.2 billion to settle 80,000 lawsuits over Zantac's alleged cancer risk, resolving 93% of pending cases without admitting wrongdoing.